Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab
复制标题
使用派姆单抗（而非纳武单抗）后出现的费舍尔综合征是一种免疫相关不良事件
DOI：
10.1007/s13760-021-01623-3
复制
发表时间：
2021
影响因子：
2.7
通讯作者：
Tamaoka Akira
中科院分区：
文献类型：
--
作者：
Nakamagoe Kiyotaka;Yamada Takeshi;Okune Sho;Moriwaki Toshikazu;Tamaoka Akira
针对程序性细胞死亡 1 (PD-1) 受体的抗体，例如派姆单抗和纳武单抗，与免疫相关不良事件 (irAE) 相关。已知这些药物会通过异常的免疫反应引起各种自身免疫性疾病。据报道，派姆单抗可引起免疫介导的神经病，例如费舍尔综合征 (FS)[1, 2]，该综合征被视为吉兰-巴利综合征 (GBS) 的一种亚型。 FS 包括三部曲：四肢/躯干共济失调、腱反射减弱和眼球运动功能障碍。然而，之前只有少数关于由于检查点免疫疗法（包括派姆单抗和纳武单抗）导致 FS 的报道 [1, 2]。在这里，我们报告了第一例患者在使用派姆单抗时出现 irAE（例如 FS），但在使用不同的 PD-1 受体抗体纳武单抗后却没有出现这种情况。 一名 73 岁的男性主诉共济失调步态。他因中分化鳞状细胞癌和淋巴结转移（cT2N4M0 IVa 期）接受了派姆单抗（每 3 周 2 毫克/公斤体重）治疗。第三个疗程派姆单抗治疗后 3 周进行胸部计算机断层扫描 (CT)
Antibodies against the programmed cell death 1 (PD-1) receptor, such as pembrolizumab and nivolumab, are associated with immune-related adverse events (irAEs). These drugs are known to cause various autoimmune diseases via abnormal immune responses. Pembrolizumab has been reported to cause immune-mediated neuropathies such as Fisher syndrome (FS)[1, 2], which is regarded as a subtype of Guillain–Barré syndrome (GBS). FS includes a trilogy of disorders: ataxia of the extremities/body trunk, decreased tendon reflexes, and ocular movement dysfunction. However, there are only a few previous reports of FS developing due to checkpoint immunotherapy including pembrolizumab and nivolumab [1, 2]. Here, we report the first case in which a patient experienced an irAE such as FS with pembrolizumab, but not after using a different antibody against PD-1 receptor, nivolumab.A 73-year-old man presented with the chief complaint of ataxic gait. He was administered pembrolizumab (2 mg/kg body weight every 3 weeks) for moderately differentiated squamous cell carcinoma and metastasis to the lymph nodes (cT2N4M0 stage IVa). Chest computed tomography (CT) performed 3 weeks after the third course of pembrolizumab
GQ1b-血清阴性米勒费希尔综合征与派姆单抗相关。
影响因子：
2.9
作者：
K. Green;A. Levine;Jayne Ward;D. Kaufman
通讯作者：
D. Kaufman